45 results
8-K
EX-99.3
IKNA
Ikena Oncology Inc
15 May 23
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
9:09am
on or about May 17, 2023, subject to satisfaction of customary closing conditions. The Company anticipates the net proceeds of the offering, together … to market and other conditions and the satisfaction of customary closing conditions related to the offering. A further list and description
S-3
EX-4.5
IKNA
Ikena Oncology Inc
27 Apr 22
Shelf registration
5:17pm
3.03
Payment Upon Redemption
Section 3.04
Sinking Fund
Section 3.05
Satisfaction of Sinking Fund Payments with Securities
Section 3.06
Redemption … Indentures
Article 10 SUCCESSOR ENTITY
Section 10.01
Company May Consolidate, Etc.
Section 10.02
Successor Entity Substituted
Article 11 SATISFACTION
S-3
EX-4.6
IKNA
Ikena Oncology Inc
27 Apr 22
Shelf registration
5:17pm
Section 3.03
Payment Upon Redemption
Section 3.04
Sinking Fund
Section 3.05
Satisfaction of Sinking Fund Payments with Securities
Section 3.06
Redemption … Indentures
Article 10 SUCCESSOR ENTITY
Section 10.01
Company May Consolidate, Etc.
Section 10.02
Successor Entity Substituted
Article 11 SATISFACTION
S-1/A
EX-10.2
IKNA
Ikena Oncology Inc
22 Mar 21
IPO registration (amended)
8:51am
in the Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold … of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Certificate) upon the satisfaction
S-1
EX-3.1
IKNA
Ikena Oncology Inc
5 Mar 21
IPO registration
2:59pm
payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the “Additional Consideration”), the Merger Agreement … to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation
DRS
EX-3.1
8ir849h1h1 ltcwe5t
8 Jan 21
Draft registration statement
12:00am
8-K
3aunqlv7
15 May 23
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
9:09am
DRS/A
EX-2.2
2gyr74 da
11 Feb 21
Draft registration statement (amended)
12:00am
S-1
EX-2.2
iws7yc22ftxzg
5 Mar 21
IPO registration
2:59pm
DRS/A
EX-2.1
52d9hlg7ktc
11 Feb 21
Draft registration statement (amended)
12:00am
S-1
EX-2.1
hxok tkxw752i
5 Mar 21
IPO registration
2:59pm
8-K
EX-3.1
jyaua8dgm gh
7 Aug 23
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
8:02am
S-1
EX-10.10
9lseei0n74k1vxo5j3nk
5 Mar 21
IPO registration
2:59pm
8-K
EX-10.1
jj2cva2o zaqs59u
7 Aug 23
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
8:02am
8-K
EX-2.1
ec9 x9p8zpvyzjpgg
7 Aug 23
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
8:02am
S-3
EX-1.2
yovnubbms ry8c
27 Apr 22
Shelf registration
5:17pm
S-1
EX-10.1
xk9bfjs
5 Mar 21
IPO registration
2:59pm
DRS/A
EX-10.1
ro0 rs6tut
11 Feb 21
Draft registration statement (amended)
12:00am
S-1/A
EX-10.5
5ld2v4gvzqhx2u
22 Mar 21
IPO registration (amended)
8:51am
8-K
EX-1.1
wk33k
15 May 23
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
9:09am